Arun Azad, Consultant Medical Oncologist at the world-renowned Peter MacCallum Cancer Centre, shared on X:
“Out now in The Lancet Oncology: biomarker data from TALAPRO-2 (Enza+/Tala) in mCR prostate cancer.
Key data:
- 81% concordance b/w ctDNA and tissue
- Baseline ctDNA- and CTC0 strongly prognostic
- Conversion of ctDNA and CTC at wk 9 strongly prognostic.”
Title: Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
Authors: Steven M Yip, A Douglas Laird, Neeraj Agarwal, Stefanie Zschäbitz, Karim Fizazi, Nobuaki Matsubara, Jae Young Joung, Lawrence I Karsh, Joan Carles, André P Fay, Josep M Piulats, Peter C C Fong, Glenn Liu, Lee A Albacker, Lincoln W Pasquina, Jijumon Chelliserry, Cynthia G Healy, Xun Lin, Matko Kalac, Arun A Azad
You can also read:
PR21 Trial Compares Patient-Reported Outcomes With Lu-177 PSMA-617 and Docetaxel in mCRPC
